↓ Skip to main content

Primary Immune Deficiency Treatment Consortium (PIDTC) report

Overview of attention for article published in The Journal of Allergy and Clinical Immunology, October 2013
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
50 Dimensions

Readers on

mendeley
129 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Primary Immune Deficiency Treatment Consortium (PIDTC) report
Published in
The Journal of Allergy and Clinical Immunology, October 2013
DOI 10.1016/j.jaci.2013.07.052
Pubmed ID
Authors

Linda M. Griffith, Morton J. Cowan, Luigi D. Notarangelo, Donald B. Kohn, Jennifer M. Puck, Sung-Yun Pai, Barbara Ballard, Sarah C. Bauer, Jack J.H. Bleesing, Marcia Boyle, Amy Brower, Rebecca H. Buckley, Mirjam van der Burg, Lauri M. Burroughs, Fabio Candotti, Andrew J. Cant, Talal Chatila, Charlotte Cunningham-Rundles, Mary C. Dinauer, Christopher C. Dvorak, Alexandra H. Filipovich, Thomas A. Fleisher, Hubert Bobby Gaspar, Tayfun Gungor, Elie Haddad, Emily Hovermale, Faith Huang, Alan Hurley, Mary Hurley, Sumathi Iyengar, Elizabeth M. Kang, Brent R. Logan, Janel R. Long-Boyle, Harry L. Malech, Sean A. McGhee, Fred Modell, Vicki Modell, Hans D. Ochs, Richard J. O'Reilly, Robertson Parkman, David J. Rawlings, John M. Routes, William T. Shearer, Trudy N. Small, Heather Smith, Kathleen E. Sullivan, Paul Szabolcs, Adrian Thrasher, Troy R. Torgerson, Paul Veys, Kenneth Weinberg, Juan Carlos Zuniga-Pflucker, workshop participants

Abstract

The Primary Immune Deficiency Treatment Consortium (PIDTC) is a network of 33 centers in North America that study the treatment of rare and severe primary immunodeficiency diseases. Current protocols address the natural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease through retrospective, prospective, and cross-sectional studies. The PIDTC additionally seeks to encourage training of junior investigators, establish partnerships with European and other International colleagues, work with patient advocacy groups to promote community awareness, and conduct pilot demonstration projects. Future goals include the conduct of prospective treatment studies to determine optimal therapies for primary immunodeficiency diseases. To date, the PIDTC has funded 2 pilot projects: newborn screening for SCID in Navajo Native Americans and B-cell reconstitution in patients with SCID after hematopoietic stem cell transplantation. Ten junior investigators have received grant awards. The PIDTC Annual Scientific Workshop has brought together consortium members, outside speakers, patient advocacy groups, and young investigators and trainees to report progress of the protocols and discuss common interests and goals, including new scientific developments and future directions of clinical research. Here we report the progress of the PIDTC to date, highlights of the first 2 PIDTC workshops, and consideration of future consortium objectives.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Denmark 1 <1%
Norway 1 <1%
Unknown 126 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 25 19%
Researcher 16 12%
Student > Master 13 10%
Other 12 9%
Student > Postgraduate 8 6%
Other 23 18%
Unknown 32 25%
Readers by discipline Count As %
Medicine and Dentistry 41 32%
Agricultural and Biological Sciences 14 11%
Immunology and Microbiology 8 6%
Biochemistry, Genetics and Molecular Biology 6 5%
Psychology 4 3%
Other 23 18%
Unknown 33 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2014.
All research outputs
#20,674,485
of 25,394,764 outputs
Outputs from The Journal of Allergy and Clinical Immunology
#10,289
of 11,247 outputs
Outputs of similar age
#169,101
of 223,954 outputs
Outputs of similar age from The Journal of Allergy and Clinical Immunology
#101
of 120 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,247 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.7. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,954 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 120 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.